Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

(2020) Ann S. LaCasce et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management

(2018) Stephen M. Ansell   AMERICAN JOURNAL OF HEMATOLOGY

Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies

(2018) Anja Mottok et al.   BLOOD

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

(2018) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

(2018) Craig H. Moskowitz et al.   BLOOD

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma

(2017) Fong Chun Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

(2010) A. J. Moskowitz et al.   BLOOD